Citius Pharmaceuticals to Present at Upcoming October Investor Conferences
Citius Pharmaceuticals (Nasdaq: CTXR) announced its participation in two investor conferences in October 2021. The first event is the Benzinga Rising Stars Conference on October 7, 2021, where Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. The second is the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021, with Mazur presenting at 8:55 a.m. ET. Citius is focused on critical care products in oncology, including late-stage assets like Mino-Lok® and I/ONTAK (E7777).
- None.
- None.
CRANFORD, N.J., Oct. 6, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products, and stem cell therapies, today announced that it will present at two investor conferences during the month of October 2021.
EVENT: Benzinga Rising Stars: Catalytic Small Cap Growth Conference
DATE: Thursday, October 7, 2021
Citius Executive Chairman Leonard Mazur will present at 9:05 a.m. ET. His presentation will be available for viewing on Benzinga's live stream channel.
EVENT: Dawson James Securities 6th Annual Small Cap Growth Conference
DATE: Thursday, October 21, 2021
Citius Executive Chairman Leonard Mazur will present at 8:55 a.m. ET in Track 1 and will be available for 1-on-1 meetings with registered conference attendees. The conference will be held October 20-21 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida. A webcast of the presentation will be available on the Events page of the Citius Investors website.
At the conferences, Mr. Mazur will discuss the Company's growing pipeline of therapies targeting unmet medical needs consisting of two late-stage assets completing Phase 3 trials, three potential first-and-only prescription treatments in their indications, and a next-generation stem cell therapy program.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Investor Relations and Corporate Communications
T: 908-967-6677 x113
E: ir@citiuspharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-upcoming-october-investor-conferences-301394276.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
When is Citius Pharmaceuticals presenting at the Benzinga Rising Stars Conference?
What date will Citius Pharmaceuticals present at the Dawson James Securities Conference?
Who will represent Citius Pharmaceuticals at the upcoming investor conferences?
What are the key product candidates Citius Pharmaceuticals is discussing at the conferences?
Where can I watch Citius Pharmaceuticals' presentation at the Benzinga Rising Stars Conference?
